Danaher is acquiring Masimo in a $10 billion deal aimed at expanding its diagnostics portfolio and deepening its presence in acute care settings. The move reflects a broader industry shift toward consolidation and integrated care, as large healthcare companies seek scale and more continuous clinical data inside hospitals.
Patient care improves when people get accurate test results from an excellent diagnostic company.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Danaher Corp. (NYSE:DHR) agreed to pay about $6.8 billion in cash for Beckman Coulter Inc. (NYSE:BEC), ending weeks of jockeying for the Brea, Calif.-based diagnostics player.